on MEDIAN TECHNOLOGIES (EPA:ALMDT)
Eyonis Inc. awarded for its lung cancer screening tool
Eyonis Inc, a subsidiary of Median Technologies, won the "Rising Star" award at the Digital Health & AI Awards 2026. This award was given for the eyonis® LCS solution, which uses artificial intelligence to improve lung cancer screening.
eyonis® LCS is the first FDA-cleared and CE-marked AI solution combining detection and diagnosis of pulmonary nodules. In one study, it demonstrated a sensitivity of 93.3% and a specificity of 92.4%, surpassing traditional methods.
This recognition highlights the potential impact of AI on healthcare, with a reduction in false positives and false negatives, and improved patient care. The software is now available in Europe and the United States.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDIAN TECHNOLOGIES news